5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase

E. Fontana, E. Lee, E. Rosen, D. Spigel,M. Højgaard,S. Lheureux, N.B. Mettu,L. Carter, R. Plummer, P. Manley, D. Ulanet, V. Rimkunas,I.M. Silverman, J. O'Connell,R. McDougall, M. Wainszelbaum, Y. Xu,M. Koehler,A.J. Fretland,T.A. Yap

Annals of Oncology（2022）

引用 2|浏览3

暂无评分

摘要

Dose-finding studies typically establish a maximum tolerated dose, a recent shift from this “more is better” approach towards long-term tolerability is of interest. The ongoing RP-3500 TRESR study (NCT04497116) used a comprehensive, non-randomized, dose-finding approach, focusing on longer-term tolerability to establish a patient (pt)-specific therapeutic dose level.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要